Guizhou Xinbang Pharmaceutical Co., Ltd. 2025 Annual Report of Independent Director (Liu Jie)
As an independent director of Guizhou Xinbang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), I have strictly followed the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Corporate Governance Guidelines for Listed Companies," the "Administrative Measures for Independent Directors of Listed Companies," and other relevant laws, regulations, normative documents, and the "Articles of Association" and the "Work System for Independent Directors" to diligently and faithfully perform my duties as an independent director. I actively attended relevant meetings, carefully reviewed all proposals submitted to the board of directors, and fully exercised the independent role of an independent director, effectively safeguarding the legitimate rights and interests of the company and all investors, especially small and medium investors. I hereby report on my performance of independent director duties in 2025 as follows:
I. Basic Information
I, Liu Jie, am a Chinese national, born in 1979, with no permanent overseas residency. I hold a Ph.D. in Accounting from Xiamen University and am a professor at Guizhou University of Finance and Economics. I currently serve as an external director of Guizhou Moutai Distillery (Group) Co., Ltd., an external director of Guiyang Guanshanhu Investment Development Holding Co., Ltd., an independent director of Guizhou Sandu Rural Commercial Bank Co., Ltd., and a financial advisor to Yunyan District Qianling Medical Hospital. I have served as an independent director of the Company since May 2023.
I have conducted a self-assessment of my independence during the reporting period and submitted the self-assessment results to the board of directors. Based on the self-assessment, my appointment complies with the requirements regarding the independence of independent directors stipulated in the "Administrative Measures for Independent Directors of Listed Companies," other relevant laws, regulations, normative documents, the "Articles of Association," and the "Work System for Independent Directors," and there are no circumstances that affect my independence.
II. Performance of Duties
(I) Attendance at Board and Shareholder Meetings
In 2025, I actively attended the Company's board and shareholder meetings. At these meetings, I carefully read the proposals and exercised my voting rights with prudence, safeguarding the overall interests of the Company and the interests of small and medium investors, thereby fulfilling my duties as an independent director. My attendance at meetings is as follows:
| Name | Number of Board Meetings to Attend | Number of In-Person Board Meetings Attended | Number of Board Meetings Attended by Communication | Number of Board Meetings Attended by Proxy | Number of Absent Board Meetings | Whether Continuously Absent for Two Consecutive Meetings | Number of Shareholder Meetings Attended |
|---|---|---|---|---|---|---|---|
| Liu Jie | 4 | 1 | 3 | 0 | 0 | No | 2 |
In 2025, the convening and holding of the Company's board and shareholder meetings complied with relevant laws, regulations, and normative documents. Major operational decisions and other significant matters were handled in accordance with prescribed procedures. I voted in favor of all proposals reviewed at the board meetings; I raised no objections to other company matters; and I did not miss any board meetings.
(II) Participation in Board Special Committee Work
In 2025, I served as the Chairman of the Audit Committee and a member of the Nomination Committee of the Ninth Board of Directors. I strictly exercised my authority in accordance with relevant regulations and fully participated in the meetings of the special committees to which I was appointed. I carefully reviewed all proposals and expressed my opinions. In 2025, the Company's Ninth Board of Directors' Audit Committee held 4 meetings, and the Ninth Board of Directors' Nomination Committee held 1 meeting. The work of the special committees is detailed as follows: